{"filings":[{"id":2105959,"accession_number":"0001294133-26-000032","cik":1294133,"company_name":"Inogen Inc","ticker":"INGN","form_type":"8-K","filed_at":"2026-08-06T20:10:33+00:00","items":["2.02","9.01"],"status":"ready","headline":"Inogen Q2 revenue $95.1M (+3% YoY); raises FY adjusted EBITDA guidance to ~$4.0M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $95.1M (+3% YoY); international revenue $41.3M (+14.8% YoY).","GAAP net loss $3.9M vs $4.2M loss prior year; adjusted EBITDA positive $2.4M vs $2.1M.","Raised FY 2026 adjusted EBITDA guidance to ~$4.0M (up 48% from 2025); revenue guidance $355M-$361M.","Cash $106.8M, no debt; repurchased 1.15M shares for $7.5M in H1 2026.","Launched Rove 6 in Canada; completed Simeox H study enrollment in China; added Andy Reding as COO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":178962550.47872344,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1387838,"accession_number":"0001294133-26-000025","cik":1294133,"company_name":"Inogen Inc","ticker":"INGN","form_type":"8-K","filed_at":"2026-07-01T20:09:09+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Inogen appoints Andy Reding as COO effective July 6, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Andy Reding appointed to newly created COO role, effective July 6, 2026.","Reding previously Chief Commercial Officer at Viant Medical and VP/GM at Hillrom Respiratory Health.","Compensation: $500k base salary, 70% target bonus, $100k sign-on bonus, 130,000 RSUs vesting over 3 years.","Severance: 12 months base salary if terminated without cause outside change of control; 24 months within change of control period.","Inducement equity award granted under Nasdaq Rule 5635(c)(4)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":178962550.47872344,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1000997,"accession_number":"0001294133-26-000021","cik":1294133,"company_name":"Inogen Inc","ticker":"INGN","form_type":"8-K","filed_at":"2026-06-11T20:32:10+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Inogen shareholders approve 750,000-share equity plan increase; declassification vote fails","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Class III directors Glenn Boehnlein and Mira Sahney elected with 17.3M and 13.3M votes for, respectively.","Ratification of Deloitte & Touche as FY2026 auditor approved (20.4M for, 407K against).","Advisory vote on executive compensation passed (17.3M for, 921K against).","Board declassification amendment failed (17.9M for, 154K against; did not meet required majority).","Amended 2023 Equity Incentive Plan approved, adding 750,000 shares (16.2M for, 2.0M against)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":178962550.47872344,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91971,"accession_number":"0001294133-26-000014","cik":1294133,"company_name":"Inogen Inc","ticker":"INGN","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Inogen Q1 revenue up 3.4% to $85.1M; net loss widens to $8.3M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net loss of $8.3M vs $6.2M loss in Q1 2025; adjusted net loss $4.0M vs $2.9M.","Adjusted EBITDA turned negative at -$1.4M vs +$0.04M a year ago on R&D investments.","Cash and securities $111.5M, no debt; $30M share repurchase authorized, $1.9M executed.","Introduced Aurora CPAP masks in U.S. and launched Rove 6 POC in Brazil.","Appointed Jason Richardson as CFO and Dominic Hulton as CMO; reiterated full-year 2026 revenue guidance."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.3,"consensus_revenue_estimate":null,"consensus_revenue_actual":85109000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":178962550.47872344,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91970,"accession_number":"0001193125-26-143703","cik":1294133,"company_name":"Inogen Inc","ticker":"INGN","form_type":"8-K","filed_at":"2026-04-06T23:59:59+00:00","items":["1.01","5.02","7.01","9.01"],"status":"ready","headline":"Inogen appoints Vafa Jamali to board, enters cooperation agreement with Kent Lake","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Vafa Jamali appointed as independent Class I director effective June 15, 2026 or 2026 annual meeting.","Jamali previously CEO of ZimVie and SVP/President of Medtronic's $3B Respiratory, GI & Informatics division.","Cooperation agreement with Kent Lake includes standstill, voting commitment, and 4.99% ownership cap.","Jamali to receive $180k initial RSU grant, plus annual cash fees of $60k for board and committee roles.","Kent Lake agreed to vote shares per board recommendations except on extraordinary transactions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":178962550.47872344,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102412,"accession_number":"0001193125-26-131855","cik":1294133,"company_name":"Inogen Inc","ticker":"INGN","form_type":"8-K","filed_at":"2026-03-30T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Inogen names Jason Richardson CFO, appoints CMO and VP Sales; reaffirms 2026 guidance","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jason Richardson appointed CFO effective April 6, 2026; previously CFO of Baxter's Health System & Technologies segment.","Michael Bourque steps down as CFO on April 6, remains Senior Advisor through June 30, 2026.","Dominic Hulton appointed CMO effective April 1, 2026; previously VP International Marketing at Insulet.","Corey Moritz appointed VP U.S. Business to Business Sales, started March 9; formerly CCO at Rhythm Healthcare.","Company reaffirms Q1 and full year 2026 financial outlook provided on February 24, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":178962550.47872344,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102411,"accession_number":"0001193125-26-066968","cik":1294133,"company_name":"Inogen Inc","ticker":"INGN","form_type":"8-K","filed_at":"2026-02-24T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Inogen reports FY2025 revenue $348.7M (+3.9%); net loss narrows to $22.7M; first positive adj. EBITDA in four years","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $348.7M (+3.9% YoY); net loss $22.7M improved from $35.9M loss in 2024.","Adjusted EBITDA turned positive at $2.7M (vs -$9.5M in 2024); Q4 adj. EBITDA -$1.7M improved from -$3.6M.","Cash and equivalents $120.9M with zero debt; Board authorized $30M share repurchase program through Dec 2027.","International POC sales grew 18.4% in 2025; introduced new products Voxi 5, Aurora CPAP masks, Simeox airway clearance.","Total gross margin 44.2% in 2025 vs 46.1% in 2024 due to channel mix."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.86,"consensus_revenue_estimate":null,"consensus_revenue_actual":348668000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":178962550.47872344,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102410,"accession_number":"0001193125-26-009878","cik":1294133,"company_name":"Inogen Inc","ticker":"INGN","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Inogen prelim Q4 rev ~$82M (+2% YoY); FY25 rev ~$349M (+4%); order delays into H1 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 preliminary revenue ~$82M, up ~2% YoY; full-year 2025 ~$349M, up ~4% YoY.","Company expects to achieve positive Adjusted EBITDA for full-year 2025.","Shift in timing of a few large customer orders from Q4 2025 to H1 2026 caused disappointment.","Full-year highlights: launches of Voxi 5 concentrator and Aurora Masks in U.S.; revenue growth and progress toward profitability.","Full Q4/FY2025 results and 2026 guidance to be announced on February 24, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.86,"consensus_revenue_estimate":null,"consensus_revenue_actual":348668000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":178962550.47872344,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118685,"accession_number":"0001193125-25-265750","cik":1294133,"company_name":"Inogen Inc","ticker":"INGN","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Inogen Q3 revenue $92.4M (+4% YoY); adj. EBITDA positive $2.3M; raises FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $92.4M, up 4% YoY; seventh consecutive quarter of mid-single-digit growth.","GAAP net loss $5.3M vs $6.0M loss; adjusted net loss $0.5M vs $2.6M loss.","Adjusted EBITDA $2.3M (third consecutive positive quarter); full-year adj. EBITDA guidance raised to ~$2M.","Cash $124.5M, no debt; initiated limited U.S. release of Simeox airway clearance device.","Gross margin 44.7% down from 46.5% due to higher B2B sales mix."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.59,"consensus_revenue_estimate":null,"consensus_revenue_actual":266947000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":178962550.47872344,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135190,"accession_number":"0000950170-25-105080","cik":1294133,"company_name":"Inogen Inc","ticker":"INGN","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Inogen Q2 2025 revenue $92.3M (+4% YoY); raises full-year revenue guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $92.3M, up 4% YoY; sixth consecutive quarter of mid-single-digit growth.","GAAP net loss $4.2M; adjusted net loss $0.7M, improved from $1.6M loss a year ago.","Adjusted EBITDA positive $2.1M, second consecutive quarter; operating cash flow $4.4M.","Cash and marketable securities $123.7M, no debt outstanding.","Raising full-year 2025 revenue expectations; new product Voxi 5 introduced."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.4,"consensus_revenue_estimate":null,"consensus_revenue_actual":174557000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":178962550.47872344,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135189,"accession_number":"0000950170-25-099624","cik":1294133,"company_name":"Inogen Inc","ticker":"INGN","form_type":"8-K","filed_at":"2025-07-29T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Inogen appoints Mary Wright as CAO, designates EVP Yi Boyer as executive officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jennifer Yi Boyer designated as executive officer and Section 16 officer effective July 28, 2025; she serves as EVP, Enterprise Enablement and CHRO.","Mary Wright appointed Chief Accounting Officer effective July 28, 2025; CFO Michael Bourque remains principal accounting officer.","Yi Boyer receives $430K base salary, target bonus 50% of base; Wright receives $312K base, target bonus 35%.","Both appointments are internal promotions; no changes to board or other executive roles."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":178962550.47872344,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152166,"accession_number":"0000950170-25-074437","cik":1294133,"company_name":"Inogen Inc","ticker":"INGN","form_type":"8-K","filed_at":"2025-05-19T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Inogen stockholders approve 2023 equity incentive plan amendment increasing share reserve by 750,000 shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["20.9M shares (77.87% of outstanding) present at the annual meeting.","Amended and Restated 2023 Equity Incentive Plan approved, adding 750,000 shares to the reserve.","Class II directors Kevin King, Mary Kay Ladone, and Kevin R.M. Smith elected.","Deloitte & Touche LLP ratified as independent auditor for fiscal year 2025.","Advisory vote on executive compensation passed with 16.7M votes for, 1.6M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":178962550.47872344,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152165,"accession_number":"0000950170-25-065644","cik":1294133,"company_name":"Inogen Inc","ticker":"INGN","form_type":"8-K","filed_at":"2025-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Inogen Q1 2025 revenue $82.3M (+5.5% YoY); adjusted EBITDA turns positive","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $82.3M, up 5.5% YoY (7.1% constant currency) on higher B2B demand.","GAAP net loss narrowed to $6.2M from $14.6M; adjusted net loss $2.9M vs $10.4M.","Adjusted EBITDA improved to positive $0.04M from negative $7.6M in prior year.","Cash $122.5M, no debt; operating expense down 13.1% to $44.0M on lower consulting."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":82280000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":178962550.47872344,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170993,"accession_number":"0000950170-25-026636","cik":1294133,"company_name":"Inogen Inc","ticker":"INGN","form_type":"8-K","filed_at":"2025-02-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Inogen Q4 revenue up 5.5% to $80.1M; full-year revenue up 6.4%; operating loss narrows significantly","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $80.1M (+5.5% YoY); gross margin 45.3% (vs 37.1% YoY) on lower raw material costs and efficiencies.","Q4 GAAP net loss $9.8M improved from $26.6M; adjusted net loss $5.8M; adjusted EBITDA negative $3.6M.","Full-year 2024 revenue $335.7M (+6.4%); operating loss $42.5M (improved from $109.4M); cash $117.4M, no debt.","Company provides 2025 growth outlook; announced strategic collaboration with Yuwell to expand product portfolio and global reach.","Pending U.S. introduction of Simeox airway clearance therapy highlighted as key future growth driver."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.52,"consensus_revenue_estimate":null,"consensus_revenue_actual":335705000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":178962550.47872344,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170992,"accession_number":"0000950170-25-012334","cik":1294133,"company_name":"Inogen Inc","ticker":"INGN","form_type":"8-K","filed_at":"2025-02-03T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Inogen appoints Mira Kirti Sahney to board; Tom West retires effective Jan 30, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mira Sahney appointed to Inogen board effective Jan 31, 2025 as Class III director; term expires at 2026 annual meeting.","Tom West resigned from board and committees effective Jan 30, 2025, not due to any disagreement with Inogen.","Sahney brings Medtronic, Hyalex Orthopaedics, Smith+Nephew, and Myomo experience; joins Nominating/Governance and Compliance committees.","Initial restricted stock unit award of 9,112 shares vesting May 14, 2025; annual cash retainer $45,000 plus committee fees."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":178962550.47872344,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170991,"accession_number":"0000950170-25-008986","cik":1294133,"company_name":"Inogen Inc","ticker":"INGN","form_type":"8-K","filed_at":"2025-01-27T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Inogen partners with Yuwell; receives ~$27.2M investment for 9.9% stake at $10.36/share","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Strategic collaboration with Jiangsu Yuyue to distribute respiratory products in US/Europe and expand into China.","Yuwell affiliate to purchase 2,626,425 shares at $10.36/share, totaling ~$27.2M (9.9% equity).","Closing expected in Q1 2025, subject to customary conditions; registration rights granted after 180 days.","Collaboration aims to broaden Inogen's product portfolio, R&D pipeline, and geographic reach.","Press release issued Jan 26, 2025; agreements effective immediately, equity purchase to close Q1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":178962550.47872344,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170990,"accession_number":"0000950170-25-004824","cik":1294133,"company_name":"Inogen Inc","ticker":"INGN","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Inogen reports prelim Q4 rev $79M-$80M (+4-5%); FY24 rev $334.5M-$335.5M (+6%), beats guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 preliminary revenue of $79M-$80M, up 4-5% YoY.","Full-year 2024 preliminary revenue of $334.5M-$335.5M, up 6% YoY, exceeding prior guidance of $329M-$331M.","Driven by strong double-digit B2B revenue growth; DTC revenue stabilization ongoing.","Launched Rove 4 and received FDA clearance for SIMEOX 200 during Q4.","Official Q4/FY results and conference call scheduled for Feb 25, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.52,"consensus_revenue_estimate":null,"consensus_revenue_actual":335705000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":178962550.47872344,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187969,"accession_number":"0000950170-24-140955","cik":1294133,"company_name":"Inogen Inc","ticker":"INGN","form_type":"8-K","filed_at":"2024-12-30T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Inogen receives FDA 510(k) clearance for SIMEOX 200, triggering $13M milestone payment","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA cleared SIMEOX 200 for airway clearance and bronchial drainage in patients with chronic lung diseases.","Clearance triggers $13M cash earnout payment to Physio-Assist sellers under July 2023 purchase agreement.","Device targets mucus hypersecretion in Bronchiectasis, COPD, Cystic Fibrosis, and Primary Ciliary Dyskinesia.","Inogen plans limited U.S. launch in 2025 via existing HCP, B2B, and direct-to-patient channels."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":178962550.47872344,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187968,"accession_number":"0000950170-24-123329","cik":1294133,"company_name":"Inogen Inc","ticker":"INGN","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Inogen Q3 revenue up 5.8% to $88.8M; adjusted EBITDA turns positive $0.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $88.8M (+5.8% YoY) driven by business-to-business gains; direct-to-consumer and rental revenue fell.","GAAP net loss narrowed to $6.0M from $45.7M; adjusted net loss $2.6M from $8.5M.","Adjusted EBITDA positive $0.5M vs negative $5.5M in Q3 2023; gross margin improved to 46.5% from 40.2%.","Operating expenses fell 39% to $49.1M (prior year included goodwill impairment).","Cash $124.3M, no debt; CEO cites progress toward sustainable profitability."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":255624000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":178962550.47872344,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204479,"accession_number":"0000950170-24-091800","cik":1294133,"company_name":"Inogen Inc","ticker":"INGN","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Inogen Q2 revenue up 6.1% to $88.8M; net loss narrows to $5.6M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $88.8M (+6.1% YoY) driven by international and domestic B2B sales.","GAAP net loss -$5.6M vs -$9.8M YoY; adjusted net loss -$1.6M vs -$5.8M.","Gross margin improved to 48.1% from 40.7% YoY on lower component costs.","Adjusted EBITDA turned positive at $1.3M from -$3.2M YoY.","Cash & equivalents $121.2M; no debt outstanding."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.86,"consensus_revenue_estimate":null,"consensus_revenue_actual":166790000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":178962550.47872344,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204478,"accession_number":"0000950170-24-088682","cik":1294133,"company_name":"Inogen Inc","ticker":"INGN","form_type":"8-K","filed_at":"2024-07-31T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Inogen EVP & General Counsel Jason Somer separates effective July 19; enters transition agreement","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Separation date July 19, 2024; role as EVP and General Counsel ended.","Transition agreement signed July 26 provides 12 months base salary continuation ($13,269.23 per pay period) and COBRA reimbursement for up to 12 months.","All unvested equity awards forfeited; vested options remain exercisable per stock agreements.","Employee agrees to cooperate for one year and releases all claims."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":178962550.47872344,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204477,"accession_number":"0000950170-24-081526","cik":1294133,"company_name":"Inogen Inc","ticker":"INGN","form_type":"8-K","filed_at":"2024-07-03T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Inogen appoints Kevin Smith as GC and EVP Business Development; Jason Somer departs July 19","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jason Somer, EVP, General Counsel & Secretary, to separate from Inogen on July 19, 2024.","Kevin P. Smith appointed as EVP, Business Development, General Counsel & Secretary, effective July 22, 2024.","Smith will receive base salary of $420,000, target bonus of 50%, and $500,000 in RSUs vesting over 3 years.","Smith previously served as GC and EVP Business Development at Sirtex Medical since 2018.","Separation and appointment are part of leadership transition; Smith's employment agreement filed as Exhibit 10.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":178962550.47872344,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":221278,"accession_number":"0000950170-24-070900","cik":1294133,"company_name":"Inogen Inc","ticker":"INGN","form_type":"8-K","filed_at":"2024-06-07T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Inogen stockholders approve amended 2023 equity plan, elect directors at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved Amended & Restated 2023 Equity Incentive Plan: 14,014,481 for, 2,868,882 against, 79,455 abstentions (2,335,280 broker non-votes).","Plan increased authorized shares by 1,200,000 and removed 'liberal' share counting for stock options/SARs.","Class I directors elected: Elizabeth Mora (8,127,945 for, 8,834,873 withheld) and Heather Rider (10,805,031 for, 6,157,787 withheld).","Ratification of Deloitte & Touche as auditor for FY2024 approved (19,159,675 for, 135,625 against).","Advisory vote on executive compensation passed: 15,676,226 for, 1,214,214 against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":178962550.47872344,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":221277,"accession_number":"0000950170-24-060589","cik":1294133,"company_name":"Inogen Inc","ticker":"INGN","form_type":"8-K","filed_at":"2024-05-15T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Inogen CMO Stanislav Glezer departs; severance includes 12-month salary & COBRA","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Stanislav Glezer separated as EVP R&D and Chief Medical Officer effective April 11, 2024.","Severance: 12 months base salary of $505,000 (26 pay periods) and COBRA premium reimbursement for 12 months.","Unvested equity awards forfeited; vested stock options remain exercisable per plan terms.","No annual bonus owed; tuition repayment for CEO program waived.","Separation agreement includes standard release of claims and confidentiality obligations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":178962550.47872344,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":221276,"accession_number":"0000950170-24-054483","cik":1294133,"company_name":"Inogen Inc","ticker":"INGN","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Inogen Q1 revenue up 8.1% to $78M; net loss narrows from $20.3M to $14.6M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $78.0M (+8.1% YoY) driven by higher international and domestic B2B sales.","GAAP net loss $14.6M vs $20.3M YoY; adjusted net loss $10.4M vs $14.5M.","Gross margin 44.1% up from 42.6%, helped by lower component costs.","Operating expenses down 3.8% to $50.6M; cash $119.8M, no debt outstanding.","CEO cites solid start; focused on revenue growth, profitability, and innovation pipeline."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.62,"consensus_revenue_estimate":null,"consensus_revenue_actual":78025000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":178962550.47872344,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":221275,"accession_number":"0000950170-24-044416","cik":1294133,"company_name":"Inogen Inc","ticker":"INGN","form_type":"8-K","filed_at":"2024-04-15T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Inogen EVP R&D & Chief Medical Officer Stanislav Glezer to depart by May 3, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mutual separation of Dr. Stanislav Glezer, EVP R&D and Chief Medical Officer, effective on or before May 3, 2024.","Company expects to enter a separation agreement with benefits consistent with his existing 2021 severance agreement.","No successor named; disclosure of separation agreement terms to be filed later.","Glezer was responsible for R&D and clinical strategy; departure leaves a key leadership gap."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":178962550.47872344,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240835,"accession_number":"0000950170-24-021113","cik":1294133,"company_name":"Inogen Inc","ticker":"INGN","form_type":"8-K","filed_at":"2024-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Inogen Q4 revenue $75.9M (-14% YoY); FY net loss $102.4M, adj EBITDA -$37.8M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $75.9M vs $88.1M YoY; full-year revenue $315.7M vs $377.2M in 2022.","Q4 GAAP net loss $26.6M vs $56.6M loss YoY; adjusted net loss $19.4M vs $13.0M loss.","Full-year GAAP net loss $102.4M vs $83.8M loss; adjusted EBITDA -$37.8M vs -$13.5M.","Cash, equivalents and marketable securities $128.5M, no debt; gross margin improved to 37.1% in Q4.","New CCO Grégoire Ramade and CFO Michael Bourque appointed; focus on Physio-Assist U.S. launch."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.42,"consensus_revenue_estimate":null,"consensus_revenue_actual":315660000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":178962550.47872344,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240834,"accession_number":"0000950170-24-006969","cik":1294133,"company_name":"Inogen Inc","ticker":"INGN","form_type":"8-K","filed_at":"2024-01-24T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Inogen appoints Michael Bourque as CFO effective March 4, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Michael Bourque appointed EVP, CFO and Treasurer; succeeds interim CFO Mike Sergesketter who stays for transition.","Annual base salary of $425,000; target bonus of 60% of base; $100,000 sign-on bonus (pro-rata clawback for 2 years).","Equity award of 150,000 RSUs/PSUs (75k time-based, 75k performance-based; up to 150k PSUs for overachievement).","Severance: 12 months base salary + COBRA if terminated without cause; 24 months if within change of control period.","Bourque previously CFO of Chase Corporation (NYSE:CCF); also CFO of Analogic and VP Finance at Axcelis Technologies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":178962550.47872344,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240833,"accession_number":"0000950170-24-002303","cik":1294133,"company_name":"Inogen Inc","ticker":"INGN","form_type":"8-K","filed_at":"2024-01-05T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Inogen appoints Grégoire Ramade as Chief Commercial Officer effective Jan 2, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Grégoire Ramade, previously SVP International Sales since Nov 2023, named CCO.","Annual base salary of €364,000; target bonus 60% of base salary.","Severance: 12 months base salary if terminated not for cause (non-CIC); 24 months if within 12 months post-change-of-control.","First two quarters guarantee quarterly target at 50% of gross annual base salary.","Prior role: SVP & CCO at Vapotherm, Inc. (Oct 2020 – Oct 2023)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":178962550.47872344,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":258335,"accession_number":"0000950170-23-066108","cik":1294133,"company_name":"Inogen Inc","ticker":"INGN","form_type":"8-K","filed_at":"2023-11-27T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Inogen officer Nabil Shabshab separates; receives $1.4M severance, resigns from board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Shabshab's employment ended Nov 10, 2023; entered separation agreement on Nov 22, 2023.","Severance of $1.4M paid over 24 months at $58,333.33/month, plus 24-month COBRA reimbursement.","Equity awards eligible for double-trigger vesting acceleration if change of control within 3 months after separation.","Retains $8,053 in airfare credits; resigns from board effective Nov 22, 2023, no disagreement with company.","Reaffirms confidentiality obligations; returns company property; assigns inventions to Inogen."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":178962550.47872344,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":258334,"accession_number":"0000950170-23-062492","cik":1294133,"company_name":"Inogen Inc","ticker":"INGN","form_type":"8-K","filed_at":"2023-11-13T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Inogen names Kevin Smith President and CEO; new compensation includes $1.7M sign-on bonus","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Kevin Smith appointed President and CEO effective Nov 10, 2023, succeeding Nabil Shabshab who departed same day.","Smith brings over 20 years med-device leadership, most recently CEO of Sirtex Medical.","Compensation: $700K salary, 100% target bonus, $1.7M sign-on bonus (two installments), 170K equity (RSUs + PSUs).","Full-year 2023 financial guidance reaffirmed; company will skip Stifel and Piper Sandler conferences."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":178962550.47872344,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":258333,"accession_number":"0000950170-23-060245","cik":1294133,"company_name":"Inogen Inc","ticker":"INGN","form_type":"8-K","filed_at":"2023-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Inogen Q3 revenue $84.0M, down 20.3% YoY; GAAP net loss $45.7M from $32.9M impairment","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $84.0M vs $105.4M in Q3 2022, down 20.3% YoY.","GAAP net loss $45.7M vs $9.5M loss YoY; includes $32.9M non-cash impairment.","Adjusted net loss $8.5M vs $4.1M loss; Adjusted EBITDA loss $5.5M vs $1.2M loss.","Completed acquisition of Physio-Assist SAS, adding airway clearance portfolio.","Cash $138.0M, no debt; focusing on returning to revenue growth."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":239764000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":178962550.47872344,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":275641,"accession_number":"0000950170-23-048471","cik":1294133,"company_name":"Inogen Inc","ticker":"INGN","form_type":"8-K","filed_at":"2023-09-18T23:59:59+00:00","items":["2.01","7.01","9.01"],"status":"ready","headline":"Inogen completes acquisition of Physio-Assist for ~$32M cash plus up to $13M earnout","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Paid ~$32M cash at closing, subject to net debt adjustment; potential earnout up to $13M if FDA clearance within 4 years.","Physio-Assist's Simeox airway clearance device targets bronchiectasis; 400k-490k US patient population.","Simeox CE-marked, sold in Europe/Asia/Middle East; Inogen to pursue FDA submission.","Expected immaterial to 2023 revenue, immediately accretive to gross margin, accretive to adjusted earnings by 2027.","Recurring revenue from disposables in addition to capital sales per device."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":178962550.47872344,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":275640,"accession_number":"0000950170-23-046888","cik":1294133,"company_name":"Inogen Inc","ticker":"INGN","form_type":"8-K","filed_at":"2023-09-07T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Inogen CFO Kristin Caltrider steps down; Mike Sergesketter named interim CFO; 2023 guidance reaffirmed","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Kristin Caltrider steps down as CFO effective Sep 11, 2023 for personal reasons; no disagreement with company.","Mike Sergesketter appointed interim CFO effective Sep 11; previously served as interim CFO in 2021-2022 and former CFO of Kimball Electronics.","Interim CFO compensation: $40k/month base salary plus $10k completion bonus upon satisfactory completion of term.","Company reaffirms 2023 revenue guidance of $315-320M and Adjusted EBITDA loss of $20-25M for full year.","Company has retained a leading executive search firm to find a permanent CFO replacement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":178962550.47872344,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":275639,"accession_number":"0000950170-23-041928","cik":1294133,"company_name":"Inogen Inc","ticker":"INGN","form_type":"8-K","filed_at":"2023-08-11T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Inogen EVP and CCO George Parr departs; enters transition agreement with 12-mo salary continuation","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["George Parr separated as EVP and Chief Commercial Officer effective July 31, 2023.","Transition agreement provides 12 months base salary continuation ($18,461.54/period) and up to 12 months COBRA reimbursement.","Parr forfeits all unvested equity awards and resigns board positions; existing vested options remain exercisable per plan terms."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":178962550.47872344,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":275638,"accession_number":"0000950170-23-039037","cik":1294133,"company_name":"Inogen Inc","ticker":"INGN","form_type":"8-K","filed_at":"2023-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Inogen Q2 revenue down 19% to $83.6M; net loss widens to $9.8M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $83.6M, down 19.1% YoY; GAAP net loss $9.8M vs $3.4M loss year ago.","Adjusted net loss $5.8M; Adjusted EBITDA loss $3.2M (vs positive $3.2M in Q2 2022).","Entered agreement to acquire Physio-Assist to add airway clearance market opportunity.","Introduced Inogen Rove 6 portable oxygen concentrator with 8-year expected service life.","Cash, cash equivalents and marketable securities $170.1M; no debt outstanding."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.31,"consensus_revenue_estimate":null,"consensus_revenue_actual":155797000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":178962550.47872344,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":275637,"accession_number":"0000950170-23-035670","cik":1294133,"company_name":"Inogen Inc","ticker":"INGN","form_type":"8-K","filed_at":"2023-07-31T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Inogen EVP and Chief Commercial Officer George Parr to separate by July 31, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["George Parr, EVP and Chief Commercial Officer, mutually agreed to separate from the Company on or before July 31, 2023.","President and CEO Nabil Shabshab will manage commercial and marketing teams on an interim basis.","No severance or compensation details disclosed; transition period to ensure business continuity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":178962550.47872344,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":275636,"accession_number":"0000950170-23-033329","cik":1294133,"company_name":"Inogen Inc","ticker":"INGN","form_type":"8-K","filed_at":"2023-07-18T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Inogen assigns headquarters lease to Sonos, pays $395K; expects new Santa Barbara lease","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Inogen assigns lease for 301 Coromar Drive, Goleta, CA headquarters to Sonos effective on or before Oct 1, 2023.","Inogen to pay Sonos $395,370.27 as part of assignment; payment due by Aug 1, 2023.","Sonos's rent obligation under lease starts Feb 1, 2024; Inogen remains secondarily liable to landlord.","Inogen expects to enter new lease in Santa Barbara area for relocation of headquarters.","Lease term expires May 31, 2031; Inogen transfers furniture, fixtures, and equipment to Sonos."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":178962550.47872344,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":275635,"accession_number":"0000950170-23-032763","cik":1294133,"company_name":"Inogen Inc","ticker":"INGN","form_type":"8-K","filed_at":"2023-07-13T23:59:59+00:00","items":["1.01","2.02","7.01","9.01"],"status":"ready","headline":"Inogen to acquire Physio-Assist for up to $45M; prelim Q2 rev $83-84M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquires Physio-Assist for ~$32M cash at closing plus up to $13M on FDA clearance milestones; total capped at $45M.","Simeox airway clearance device (CE marked) expands product line; US market opportunity estimated at 400k-490k bronchiectasis patients.","Closing expected Q4 2023 subject to French regulatory approval; Inogen provides up to $500k convertible loan pre-close.","Preliminary Q2 2023 revenue $83-84M, below expectations; updated 2023 guidance to follow on Aug 7 earnings call.","Acquisition expected to be accretive to adjusted earnings from 2027 and immediately accretive to gross margin."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":178962550.47872344,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":293179,"accession_number":"0000950170-23-026492","cik":1294133,"company_name":"Inogen Inc","ticker":"INGN","form_type":"8-K","filed_at":"2023-06-06T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Inogen stockholders approve 2023 Equity Incentive Plan, elect directors at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Stockholders approved 2023 Equity Incentive Plan, effective June 5, 2023, replacing 2014 Plan.","Plan reserves 400,000 new shares plus up to 2,950,000 from prior plan lapsed awards.","Glenn Boehnlein and Thomas A. West elected as Class III directors for three-year terms.","Advisory vote on executive compensation passed with 13.9M for, 5.4M against; frequency set to every one year.","Deloitte & Touche ratified as independent auditor for fiscal year ending December 31, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":178962550.47872344,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":293178,"accession_number":"0000950170-23-017865","cik":1294133,"company_name":"Inogen Inc","ticker":"INGN","form_type":"8-K","filed_at":"2023-05-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Inogen Q1 2023 revenue $72.2M, net loss $20.3M; sees positive adjusted EBITDA by Q4 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $72.2M, down 10.2% YoY; rental revenue up 25.4% YoY.","GAAP net loss $20.3M vs $14.2M loss in Q1 2022; adjusted net loss $14.5M vs $8.7M.","Adjusted EBITDA loss $11.8M vs $5.0M loss; expects positive adjusted EBITDA by Q4 2023.","Cash and marketable securities $174.6M; no debt outstanding.","Notified of France reimbursement for Rove 6; added two large private payers covering ~160M lives."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.88,"consensus_revenue_estimate":null,"consensus_revenue_actual":72162000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":178962550.47872344,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":313813,"accession_number":"0000950170-23-009177","cik":1294133,"company_name":"Inogen Inc","ticker":"INGN","form_type":"8-K","filed_at":"2023-03-22T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Inogen board member Kristen Miranda resigns; Tom West appointed effective April 1, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Kristen Miranda resigned as director effective March 31, 2023; not due to any disagreement with the company.","Thomas A. West appointed to Board effective April 1, 2023; will serve as Class III director and on Nominating/Governance and Compliance Committees.","West is President and CEO of Nalu Medical; previously CEO of Intersect ENT and held senior roles at Hologic and Johnson & Johnson.","West receives annual cash fees of $45,000 for Board service and $5,000 per committee, plus initial RSU award of 1,712 shares vesting by June 8, 2023.","Appointment expands board expertise in medtech and operational leadership as Inogen pursues growth transformation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":178962550.47872344,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":313812,"accession_number":"0000950170-23-004096","cik":1294133,"company_name":"Inogen Inc","ticker":"INGN","form_type":"8-K","filed_at":"2023-02-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Inogen Q4 revenue up 15.3% to $88.1M, but GAAP net loss widens to $56.6M on $52.2M intangible write-off","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $88.1M (+15.3% YoY); full-year revenue $377.2M (+5.4% YoY).","Q4 GAAP net loss $56.6M includes $52.2M loss on disposal of intangible asset; adjusted net loss $13.0M.","Full-year GAAP net loss $83.8M; adjusted net loss $26.2M; adjusted EBITDA loss $13.5M.","Gross margin fell to 33.5% in Q4 (from 50.5%) due to channel mix and higher component costs.","Cash $187M, no debt; rental revenue grew 22.5% for the year."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.67,"consensus_revenue_estimate":null,"consensus_revenue_actual":377241000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":178962550.47872344,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":313811,"accession_number":"0000950170-23-002469","cik":1294133,"company_name":"Inogen Inc","ticker":"INGN","form_type":"8-K","filed_at":"2023-02-10T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"EVP Operations Bart Sanford to separate from Inogen by March 1, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Bart Sanford, EVP Operations, will separate on or before March 1, 2023.","Sanford will provide transition services until separation, receiving base salary of $380k/year.","Subject to release conditions, Sanford gets 12 months base salary continuation and COBRA subsidy for up to 18 months.","The separation is mutual; Sanford resigns from all officer positions effective separation date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":178962550.47872344,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":313810,"accession_number":"0000950170-23-000566","cik":1294133,"company_name":"Inogen Inc","ticker":"INGN","form_type":"8-K","filed_at":"2023-01-10T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Inogen reports preliminary Q4 2022 revenue within prior guidance range","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q4 revenue $87.5M-$88.5M, YoY growth 14.5%-15.8%.","Full year 2022 revenue $376.7M-$377.7M, YoY growth 5.2%-5.5%.","FX negatively impacted Q4 revenue by ~$1.3M and FY by ~$5.3M.","Results within previous Q4 guidance of $87M-$92M; CEO cites headwinds but expects productivity improvement.","Company to announce full Q4/FY results on Feb 23, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.67,"consensus_revenue_estimate":null,"consensus_revenue_actual":377241000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":178962550.47872344,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":332276,"accession_number":"0000950170-22-026958","cik":1294133,"company_name":"Inogen Inc","ticker":"INGN","form_type":"8-K","filed_at":"2022-12-22T23:59:59+00:00","items":["2.05"],"status":"ready","headline":"Inogen abandons TAV ventilator program, expects $53.4M asset write-down in Q4 2022","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Ceased development of TAV technology from New Aera; estimates $53.4M loss on disposal of intangible assets.","Loss on inventory of $0.2-$0.3M, partially offset by $13.6-$13.7M decrease in earnout liability.","No significant future cash charges expected; disposal to be completed by Dec 31, 2022.","Decision based on lack of product compatibility, no Medicare reimbursement, and substantial additional investment needed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":178962550.47872344,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":332275,"accession_number":"0000950170-22-020979","cik":1294133,"company_name":"Inogen Inc","ticker":"INGN","form_type":"8-K","filed_at":"2022-11-02T23:59:59+00:00","items":["2.02","5.03","9.01"],"status":"ready","headline":"Inogen Q3 revenue rises 13.2% to $105.4M but swings to GAAP net loss of $9.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $105.4M (+13.2% YoY); constant currency growth 14.5%.","GAAP net loss of $9.5M vs net income of $12.2M in Q3 2021; adjusted net loss $4.1M.","Gross margin 40.6% (down from 51.2%) on higher material costs and unfavorable channel mix.","Adjusted EBITDA loss $1.2M vs positive $12.2M; cash $209.6M, no debt.","Operating expense rose 28.5% to $53.1M driven by strategic investments and earnout adjustment."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":289150000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":178962550.47872344,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":349734,"accession_number":"0000950170-22-014752","cik":1294133,"company_name":"Inogen Inc","ticker":"INGN","form_type":"8-K","filed_at":"2022-08-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Inogen Q2 revenue $103.4M (+1.8% YoY) but GAAP net loss $3.4M vs $5.1M income a year ago","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $103.4M, up 1.8% YoY (3.6% constant currency) and 28.6% sequentially from Q1; international sales and domestic rentals drove growth.","GAAP net loss of $3.4M compared to net income of $5.1M in Q2 2021; adjusted net loss $0.4M vs adjusted net income $1.8M.","Gross margin fell to 44.7% from 49.6% on higher material prices and warranty costs, partially offset by higher ASP and favorable mix.","Adjusted EBITDA was $3.2M, down from $12.4M in prior-year quarter; operating expenses rose 27.1% to $49.1M.","Cash and equivalents $223.6M as of June 30, 2022; no explicit guidance provided for remainder of year."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.77,"consensus_revenue_estimate":null,"consensus_revenue_actual":183761000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":178962550.47872344,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":366788,"accession_number":"0000950170-22-011564","cik":1294133,"company_name":"Inogen Inc","ticker":"INGN","form_type":"8-K","filed_at":"2022-06-13T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Inogen holds 2022 annual meeting; elects directors, ratifies auditor, approves pay","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Class II directors elected: King (19.2M for, 114k withhold), Ladone (19.2M for, 114k withhold), Shabshab (14.6M for, 4.7M withhold).","Ratification of Deloitte & Touche as auditor passed with 20.6M for, 8.7k against.","Advisory executive compensation approval: 18.4M for, 886k against, 31.5k abstentions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":178962550.47872344,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":366787,"accession_number":"0001564590-22-018244","cik":1294133,"company_name":"Inogen Inc","ticker":"INGN","form_type":"8-K","filed_at":"2022-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Inogen Q1 2022 revenue down 7.5% YoY to $80.4M; net loss $0.62 per share","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net loss $14.2M ($0.62/share); adjusted loss per share $0.39.","Revenue $80.4M, down 7.5% YoY, up 5.2% sequentially; domestic B2B fell 83.4% to $5.1M.","Gross margin declined 240 bps to 43.5% due to higher materials costs and temporary manufacturing shutdown.","No FY2022 revenue guidance; Q2 revenue expected to improve sequentially and be in line with Q2 2021; expects continued losses.","EU MDR submission for portable oxygen concentrators filed and under review."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.62,"consensus_revenue_estimate":null,"consensus_revenue_actual":80385000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":178962550.47872344,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-05-05T23:59:59+00:00|366787"}